Key Takeaways by Planet Today:
Hidden fatality after experimental brain therapy: A sole-patient trial in Shanghai using base editors delivered via spinal fluid ended in a severe immune reaction just one week later, yet the outcome stayed off public records and ClinicalTrials.gov for more than a year.Parents financed the work themselves: The family contributed roughly $860,000 toward development costs under arrangements later described as unusually risky and poorly safeguarded.Preclinical paper published without context: The research team’s Nature report on animal studies omitted any reference to the human case, the death, or the family’s financial role, prompting calls for fuller disclosure and possible retraction review.Regulatory gap exposed: The procedure advanced under a hospital-level provision that bypassed national approval, highlighting differences between stated Chinese biotech safeguards and on-the-ground practice.Broader implications for rare-disease trials: The episode arrives alongside more transparent, publicly discussed base-editing cases elsewhere and raises questions about how urgency, secrecy, and patient safety are balanced when technologies move from mice and monkeys into children. {alertInfo}
In late March 2025 a six-year-old girl with a rare neurodevelopmental disorder received an experimental gene-editing treatment at Shanghai’s Xinhua Hospital. Seven days later she was dead from a severe immune reaction linked to the therapy. Her parents had paid more than $860,000 to help develop it. The death was never reported publicly. An investigation by Science and Retraction Watch, published 23 July 2026, has now brought the details into the open.
The child lived with Snijders Blok-Campeau syndrome, caused by a single-base change in the CHD3 gene. The mutation left her lagging behind peers in language, motor skills and cognitive development. She spoke in simple sentences and still needed training chopsticks. Her parents, searching for any chance of improvement, turned to a team led by neuroscientist Zilong Qiu at the Songjiang Research Institute of Shanghai Jiao Tong University School of Medicine.
A First-of-Its-Kind Procedure in the Brain
The treatment used a base editor—an evolution of CRISPR technology designed to change a single DNA letter without cutting the double helix. Researchers packaged the editor into dual adeno-associated virus vectors and infused trillions of viral particles into the girl’s cerebrospinal fluid. The goal was to correct the mutation in neurons and restore production of the CHD3 protein that helps regulate brain development.
According to the ClinicalTrials.gov entry (NCT06860672), the study was registered as a safety, tolerability and preliminary-efficacy trial of a single intrathecal injection for the R1025W mutation. Enrollment was listed as one. The hospital authorized the procedure under a regulatory provision for exceptional innovative treatments that did not require prior national approval.
One month earlier, in the United States, an infant named KJ Muldoon had received a custom base-editing therapy for a different metabolic disorder at the Children’s Hospital of Philadelphia. That case was openly discussed and later recognized as a runner-up for Science’s 2025 Breakthrough of the Year. The Shanghai trial took a quieter path.
What Happened After the Infusion
Seven days after the procedure the girl died. An internal review linked the death to a severe immune reaction triggered by the therapy. One account has described the final complication as thrombotic microangiopathy. The research team returned the parents’ funds. The ClinicalTrials.gov record was never updated. No public statement was issued by the hospital, the university or the investigators.
Earlier this year the same group published a paper in Nature describing successful base editing of the equivalent mutation in a humanized mouse model and supporting experiments in non-human primates. The article reported restoration of protein levels and improvement in behavioural measures in mice, plus widespread neuronal transduction after intrathecal delivery in monkeys. It made no mention of the human patient, the financial contribution of her family, or the fatal outcome. The paper’s language simply noted that “bridging the gap between preclinical research and clinical translation remains a significant challenge.”
Nature later stated it had been unaware of the clinical events before publication. Neither Qiu nor hospital representatives responded to requests for comment from the investigating journalists.
“We did not realize how unusual and dangerous many of the arrangements were,” the girl’s father, a software engineer, later told investigators. After learning more about the missing safeguards, he said his view of the entire project changed. The family has asked the authors to withdraw the Nature paper.
Expert Concerns and Oversight Questions
Outside scientists who reviewed the available details raised several red flags. Steven Gray of the University of Texas Southwestern Medical Center, who develops viral vectors for gene therapy, stated bluntly: “This shouldn’t have gone to trial.” Critics pointed to the enormous viral dose required, limited correction rates observed in animals, and the decision to move into a child despite those signals. They have called for a full review of the Nature paper’s images and data and for complete disclosure of funding sources.
Joy Zhang, a sociologist at the University of Kent who studies Chinese science policy, has long noted the tension between rapid biotech ambition and institutional secrecy. The case, she and others argue, illustrates a gap between the safeguards China has written into regulations and the practices that can still occur at the hospital level.
The episode sits against a wider backdrop of accelerating gene-editing work for rare diseases. Base editors and related tools are advancing in multiple countries for conditions once considered untreatable. Success stories such as the Philadelphia infant show the technology’s potential when trials are conducted with rigorous oversight and transparent reporting. The Shanghai case shows the opposite side of the same coin.
How should the scientific community balance the urgency of treating rare diseases with the need for full transparency when experimental therapies fail?
What Comes Next
The parents continue to seek accountability. Experts have urged journals, regulators and research institutions to examine both the specific trial and the broader pathways that allowed a fatal outcome to remain hidden while a related preclinical paper appeared in a high-profile journal. For families facing similar diagnoses, the story is a reminder that experimental therapies, however promising in animals, still carry risks that can only be fully understood if every outcome—good or tragic—is shared.
Readers interested in related questions of brain health, developmental disorders and emerging medical technologies may also find context in earlier Planet Today reporting on dementia risk factors and on neurodevelopmental concerns linked to common medications: Up to 45% Dementia Risk Preventable: WHO Guidelines Critically Examined and Tylenol Autism Lawsuits Revived.
Disclaimer for fact-checkers: This account is based primarily on the joint investigation published by Science and Retraction Watch on 23 July 2026, cross-checked against the Nature paper (DOI: 10.1038/s41586-026-10113-6), the ClinicalTrials.gov record NCT06860672, and contemporaneous secondary reporting. Primary documents and direct institutional responses remain limited; readers are encouraged to consult the original investigation for the fullest sourcing.
The girl’s death was a private tragedy that stayed private for more than a year. Making it public does not reverse the outcome. It does, however, force a clearer conversation about the conditions under which the most powerful tools in modern biology are tested on the most vulnerable patients.